DiveRadGel Co.,Ltd.
DiveRadGel is a Japanese K.K., founded in 2024 and based in Japan, developing a dendritic-cell-targeted drug-delivery (DDS) cancer-vaccine platform engineered to eradicate solid tumors and prevent relapse. Our proprietary DDS technology selectively delivers tumor antigens(TAA, Neoantigen) to cDC1s in lymph nodes, overcoming the limitations of current immunotherapies by inducing robust, long-lasting T cell responses.
Pre-clinical highlights
• Complete regression of cold tumors and protection from re-challenge for > 18 months in mice model (with potent antigen spreading effect)
• GMP-level manufacturing of DDS technology has completed and scale-up of antigen-loaded vaccine to pilot scale is in progress.
Partnership opportunities (What we are seeking)
• Co-development of antigen-cocktail cancer vaccines incorporating your proprietary epitopes
• Combination-therapy studies integrating our vaccine with your modalities (TCR-T, radiotherapy, ICIs, etc.)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}